CCL3L3

Across TCGA pan-cancer cohorts, CCL3L3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CCL3L3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCL3L3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCL3L3 expression acts as an unfavorable survival marker.

HNSC and BRCA are the cancer types where CCL3L3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.174	0.685	.022	18	view →
BRCA	OS	Median	All	0.191	0.579	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CCL3L3–HNSC (OS)

Open the HNSC breakdown →